O agonista oral do receptor GLP-1 da Eli Lilly, Foundayo (ozaglitazona), demonstrou controle superior da hemoglobina glicada A1C e perda de peso em três estudos clínicos fundamentais para o tratamento do diabetes tipo 2.
Indianápolis, 8 de junho de 2026 /PRNewswire/ -- A Eli Lilly and Company (NYSE: LLY), fabricante do Zepbound (telapatida), anunciou hoje os resultados detalhados de três estudos cl…
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Perguntas frequentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
